title: Coagulation state in patients with Crohn's disease: the effect of infliximab therapy.
abstract: BACKGROUND
  Growing evidence has shown that coagulation processes play an important role in disease pathogenesis and/or disease progression in patients with inflammatory bowel disease. However, no study has ever focused on the possible influence of infliximab (IFX) therapy on the coagulation status in patients with Crohn's disease (CD).
  
  
  OBJECTIVE
  To investigate the difference in the coagulation biomarkers between the CD patients and the control participants, and evaluate the impact of IFX usage on the coagulation status of CD patients.
  
  
  METHODS
  A retrospective study that included a case-control study and a self-control study was designed. The medical records of CD patients and control participants were evaluated according to the inclusion and exclusion criteria. The results of laboratory tests including blood routine, coagulation, D-dimer, C-reactive protein, and erythrocyte sedimentation rate were retrieved to assess the coagulation state.
  
  
  RESULTS
  In the case-control study, almost all the parameters showed a statistically significant difference between the CD patients and the control participants, except for activated partial thromboplastin time and thrombin time (the P value ranged from 0.000 to 0.002). Most of the values of the parameters reverted to normal over time during IFX therapy in the self-control study. Moreover, the fibrinogen concentration decreased obviously after IFX infusion (P=0.000) and the D-dimer concentration also decreased obviously by about half of the start value after IFX usage (P=0.018).
  
  
  CONCLUSIONS
  IFX therapy could ameliorate the hypercoagulable state in patients with CD.
authors: aDepartment of Gastroenterology/Hepatology, Zhongnan Hospital of Wuhan University bThe Hubei Clinical Center & Key Laboratory of Intestinal & Colorectal Diseases, Wuhan, People's Republic of China.
authors: Xiaobing
authors: X
authors: Wang
authors: Ge
authors: G
authors: Wang
authors: Jinghui
authors: J
authors: Wang
authors: Shi
authors: S
authors: Liu
authors: Rui
authors: R
authors: Zhou
authors: Liping
authors: L
authors: Chen
authors: Ting
authors: T
authors: Wu
authors: Meifang
authors: M
authors: Huang
authors: Jin
authors: J
authors: Li
authors: Lu
authors: L
authors: Song
authors: Bing
authors: B
authors: Xia
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000494:pharmacology* / Q000627:therapeutic use; D001777:Blood Coagulation / Q000187:drug effects*; D001780:Blood Coagulation Tests / Q000379:methods; D016022:Case-Control Studies; D003424:Crohn Disease / Q000097:blood* / Q000188:drug therapy / Q000473:pathology; D004341:Drug Evaluation / Q000379:methods; D005260:Female; D005338:Fibrin Fibrinogen Degradation Products / Q000378:metabolism; D005765:Gastrointestinal Agents / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D000069285:Infliximab; D008297:Male; D063847:Mean Platelet Volume; D008875:Middle Aged; D010976:Platelet Count; D012189:Retrospective Studies; D055815:Young Adult
chemical_list: D000911:Antibodies, Monoclonal; D005338:Fibrin Fibrinogen Degradation Products; D005765:Gastrointestinal Agents; C036309:fibrin fragment D; D000069285:Infliximab